Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Key Highlights
- ➤Jolanda Crombach appointed general manager of Ocugen’s European affiliate
- ➤European affiliate headquartered in Amsterdam will support European regulatory submissions
- ➤OCU410 Phase 3 program targets geographic atrophy secondary to dry age-related macular degeneration
- ➤Three Phase 3 programs target retinitis pigmentosa, geographic atrophy, and Stargardt disease
- ➤Key Phase 3 data readouts expected in 2027 and 2028
Expert Statements
Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen
“As we advance our three Phase 3 modifier gene therapy programs toward regulatory submissions and potential commercialization, establishing a strong presence in Europe is an important component of our growth strategy.”
Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen
“Jolanda is ideally suited to lead this important expansion. Her extensive pharmaceutical leadership experience, deep understanding of the European healthcare environment and track record of building organizations will be invaluable as we develop our European operations and prepare to potentially bring transformative, one-time treatment gene therapies to patients.”
Jolanda Crombach, General Manager of European Affiliate, Ocugen
“I am excited to join Ocugen and contribute to the Company’s mission of developing innovative gene therapies for people living with blindness diseases.”
Jolanda Crombach, General Manager of European Affiliate, Ocugen
“Ocugen has built an innovative pipeline addressing significant unmet needs in ophthalmology, and I look forward to working with the team to establish a strong European organization and help expand access to these potentially transformative gene therapies for patients across Europe.”
* European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company’s European affiliate. Ms. Crombach, an accomplished pharmaceutical executive with more than 20 years of industry experience, will lead the Company’s newly established European affiliate, headquartered in Amsterdam, Netherlands.
“As we advance our three Phase 3 modifier gene therapy programs toward regulatory submissions and potential commercialization, establishing a strong presence in Europe is an important component of our growth strategy,” said Shankar Musunuri, PhD, MBA, Chairman, Chief Executive Officer and Co-founder of Ocugen. “Jolanda is ideally suited to lead this important expansion. Her extensive pharmaceutical leadership experience, deep understanding of the European healthcare environment and track record of building organizations will be invaluable as we develop our European operations and prepare to potentially bring transformative, one-time treatment gene therapies to patients.”
Get started
Create a free account to read the full story.